CAR T-cell Therapy

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Latest News

Syed Abbas Ali, MBBS
Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

November 22nd 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Chad Williams, PhD
Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

OncLive's Top 5 Stories of the Week in Oncology
The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

FDA
FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

November 8th 2024

Michel Delforge, MD, PhD
Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma

November 1st 2024

Latest CME Events & Activities